These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 37461248)
1. Comparative expression of TRPS1, GATA3, SOX10, mammaglobin, and GCDFP-15 in effusion specimens with breast carcinoma. Bradt A; Jing X; Smola BS; Lew M Diagn Cytopathol; 2023 Nov; 51(11):665-673. PubMed ID: 37461248 [TBL] [Abstract][Full Text] [Related]
2. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma. Yoon EC; Wang G; Parkinson B; Huo L; Peng Y; Wang J; Salisbury T; Wu Y; Chen H; Albarracin CT; Resetkova E; Middleton LP; Krishnamurthy S; Gan Q; Sun H; Huang X; Shen T; Chen W; Parwani AV; Sahin AA; Li Z; Ding Q Hum Pathol; 2022 Jul; 125():97-107. PubMed ID: 35413381 [TBL] [Abstract][Full Text] [Related]
3. Matrix Gla protein (MGP), GATA3, and TRPS1: a novel diagnostic panel to determine breast origin. Du T; Pan L; Zheng C; Chen K; Yang Y; Chen J; Chao X; Li M; Lu J; Luo R; Zhang J; Wu Y; He J; Jiang D; Sun P Breast Cancer Res; 2022 Oct; 24(1):70. PubMed ID: 36284362 [TBL] [Abstract][Full Text] [Related]
4. TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin. Almási S; Kuthi L; Sejben A; Vörös A; Nagy Á; Zombori T; Cserni G Virchows Arch; 2023 May; 482(5):861-868. PubMed ID: 37012444 [TBL] [Abstract][Full Text] [Related]
5. The diagnostic utility of trichorhinophalangeal syndrome type 1 immunohistochemistry for metastatic breast carcinoma in effusion cytology specimens. Chen CJ; Hang JF; Chen YA; Lin SJ; Chiu HM; Hsu CY; Lai CR; Yang CS Cancer Cytopathol; 2023 Apr; 131(4):226-233. PubMed ID: 36399408 [TBL] [Abstract][Full Text] [Related]
6. TRPS1 is a promising marker for all subtypes of breast cancer. Lui JW; Tsang JY; Li J; Ko CW; Tam F; Loong TC; Tse GM Histopathology; 2024 Apr; 84(5):822-836. PubMed ID: 38173281 [TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility and sensitivities of matrix Gla protein (MGP), TRPS1 and GATA3 in breast cancer: focusing on metastatic breast cancer, invasive breast carcinoma with special features, and salivary gland-type tumours. Wu Y; Chen F; Pan L; Chao X; Li M; Luo R; Chen K; Zheng C; Du T; He J; Sun P Pathology; 2024 Jun; 56(4):516-527. PubMed ID: 38570266 [TBL] [Abstract][Full Text] [Related]
8. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer. Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249 [TBL] [Abstract][Full Text] [Related]
9. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens. Shield PW; Papadimos DJ; Walsh MD Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220 [TBL] [Abstract][Full Text] [Related]
10. GATA-binding protein 3 enhances the utility of gross cystic disease fluid protein-15 and mammaglobin A in triple-negative breast cancer by immunohistochemistry. Huo L; Gong Y; Guo M; Gilcrease MZ; Wu Y; Zhang H; Zhang J; Resetkova E; Hunt KK; Deavers MT Histopathology; 2015 Aug; 67(2):245-54. PubMed ID: 25564996 [TBL] [Abstract][Full Text] [Related]
11. TRPS1 outperforms GATA3 in pleural effusions with metastatic breast carcinoma versus mesothelioma. Baban F; Koepplin JW; Ahmad M; Clarke-Brodber AL; Bois MC; Hartley CP; Sturgis CD Diagn Cytopathol; 2023 Aug; 51(8):488-492. PubMed ID: 37096814 [TBL] [Abstract][Full Text] [Related]
12. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions. Lew M; Pang JC; Jing X; Fields KL; Roh MH Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236 [TBL] [Abstract][Full Text] [Related]
13. Trichorhinophalangeal Syndrome Type 1 Is a Highly Sensitive and Specific Marker for Diagnosing Triple-Negative Breast Carcinomas on Cytologic Samples. Lynn TJ; Shi J; Liu H; Monaco SE; Prichard JW; Lin F Arch Pathol Lab Med; 2024 Jan; 148(1):e1-e8. PubMed ID: 37406296 [TBL] [Abstract][Full Text] [Related]
14. A pilot study: Comparison of TRPS1 and GATA3 immunoperoxidase staining using cytologic smears in entities reportedly positive for GATA3. Rohra P; Ding C; Yoon EC; Gan Q Cancer Cytopathol; 2022 Dec; 130(12):930-938. PubMed ID: 35790088 [TBL] [Abstract][Full Text] [Related]
15. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors. Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123 [TBL] [Abstract][Full Text] [Related]
16. Can GATA3 Immunocytochemistry be Utilized as a Reliable Diagnostic Marker for Metastatic Breast Carcinoma in Cytological Materials? A Comparative Study with Mammaglobin and GCDFP-15 Expression. Hafez NH; Shaaban HM Turk Patoloji Derg; 2018; 34(2):143-149. PubMed ID: 29235613 [TBL] [Abstract][Full Text] [Related]
17. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer. Tozbikian GH; Zynger DL Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800 [TBL] [Abstract][Full Text] [Related]
18. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology. Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030 [TBL] [Abstract][Full Text] [Related]
19. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens. Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624 [TBL] [Abstract][Full Text] [Related]
20. TRPS1 and GATA3 Expression in Invasive Breast Carcinoma With Apocrine Differentiation. Wang J; Peng Y; Sun H; Aung PP; Resetkova E; Yam C; Sahin AA; Huo L; Ding Q Arch Pathol Lab Med; 2024 Feb; 148(2):200-205. PubMed ID: 37074839 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]